

Clinical Policy: Naproxen/Esomeprazole (Vimovo)

Reference Number: CP.PMN.117

Effective Date: 06.01.18

Last Review Date: 05.26

Line of Business: Commercial, HIM/ICHRA, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Naproxen/esomeprazole magnesium (Vimovo®) is a fixed combination of naproxen, a non-steroidal anti-inflammatory drug (NSAID), and esomeprazole, a proton pump inhibitor (PPI).

FDA Approved Indication(s)

Vimovo is indicated in adult and adolescent patients 12 years of age and older weighing at least 38 kg, requiring naproxen for symptomatic relief of arthritis and esomeprazole magnesium to decrease the risk for developing naproxen-associated gastric ulcers.

The naproxen component of Vimovo is indicated for relief of signs and symptoms of:

- Osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in adults.
- Juvenile idiopathic arthritis (JIA) in adolescent patients.

The esomeprazole magnesium component of Vimovo is indicated to decrease the risk of developing naproxen-associated gastric ulcers.

Limitation(s) of use:

- Do not substitute Vimovo with the single-ingredient products of naproxen and esomeprazole magnesium.
- Vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.
- Controlled studies do not extend beyond 6 months.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Vimovo or naproxen/esomeprazole magnesium is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. All FDA-Approved Indications (must meet all):

1. Prescribed to decrease the risk of developing NSAID-induced gastric ulcers in patients with rheumatoid arthritis, JIA, osteoarthritis, or ankylosing spondylitis;
2. Age $\geq$ 12 years;
3. Weight $\geq$ 38 kg;

4. Failure of three PPIs (e.g., omeprazole, pantoprazole, lansoprazole) in combination with three different NSAIDs, unless clinically significant adverse effects are experienced or all are contraindicated;*

** For Illinois HIM requests, the step therapy requirements above do not apply as of 1/1/2026 per IL HB 5395*

5. Member must instead use the individual components (i.e., esomeprazole* and naproxen) concurrently, unless contraindicated or clinically significant adverse effects are experienced;^

**Prior authorization may be required for esomeprazole.*

^ For Illinois HIM requests, the step therapy requirements above do not apply as of 1/1/2026 per IL HB 5395

6. Member has at least one of the following risk factors for developing NSAID-induced gastric ulcers (a, b, or c);
 - a. Age > 65 years;
 - b. Member has a history of peptic ulcer disease;
 - c. Concurrent use of antiplatelets, corticosteroids, or anticoagulants;
7. If request is for brand Vimovo, member must use generic naproxen/esomeprazole, unless contraindicated or clinically significant adverse effects are experienced;
8. Dose does not exceed one of the following (a or b):
 - a. For adults and adolescent patients weighing ≥ 50 kg, both of the following (i and ii):
 - i. 1,000 mg naproxen/40 mg esomeprazole per day;
 - ii. 2 tablets per day;
 - b. For adolescent patients weighing 38 kg to < 50 kg, both of the following (i and ii):
 - i. 750 mg naproxen/40 mg esomeprazole per day;
 - ii. 2 tablets per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. All FDA Approved Indications (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. Member continues to have at least one of the following risk factors for developing NSAID-induced gastric ulcers (a, b, or c):
 - a. Age > 65 years;
 - b. Member has a history of peptic ulcer disease;
 - c. Concurrent use of antiplatelets, corticosteroids, or anticoagulants;
4. If request is for brand Vimovo, member must use generic naproxen/esomeprazole, unless contraindicated or clinically significant adverse effects are experienced;
5. If request is for a dose increase, new dose does not exceed one of the following (a or b):
 - a. For adults and adolescent patients weighing ≥ 50 kg, both of the following (i and ii):
 - i. 1,000 mg naproxen/40 mg esomeprazole per day;
 - ii. 2 tablets per day;
 - b. For adolescent patients weighing 38 kg to < 50 kg, both of the following (i and ii):
 - i. 750 mg naproxen/40 mg esomeprazole per day;
 - ii. 2 tablets per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CABG: coronary artery bypass graft
FDA: Food and Drug Administration
GI: gastrointestinal

JIA: juvenile idiopathic arthritis
NSAID: nonsteroidal anti-inflammatory drug
PPI: proton pump inhibitor

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
PPIs		
lansoprazole (Prevacid®)	NSAID-induced ulcer prophylaxis: 15 mg PO QD NSAID-associated gastric ulcer (healing): 30 mg PO QD	30 mg/day (for most indications)
omeprazole (Prilosec®)	NSAID-induced ulcer prophylaxis [†] : 20 mg PO QD	40 mg/day (for most indications)
pantoprazole (Protonix®)	NSAID-induced ulcer prophylaxis [†] : 40 mg PO QD	40 mg/day (for most GERD indications)
NSAIDs		
diclofenac (Voltaren®)	Osteoarthritis: 50 mg PO BID-TID or 75 mg PO BID Rheumatoid arthritis: 50 mg PO TID-QID, or 75 mg PO BID Ankylosing spondylitis: 25 mg PO QID with an additional 25 mg dose at bedtime	Osteoarthritis: 150 mg/day Rheumatoid arthritis: 200 mg/day Ankylosing spondylitis: 125 mg/day

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
etodolac (Lodine [®])	Osteoarthritis or rheumatoid arthritis: 400 – 500 mg PO BID	1200 mg/day
fenoprofen (Nalfon [®])	400 – 600 mg PO TID-QID	3,200 mg/day
ibuprofen (Motrin [®])	400 – 800 mg PO TID-QID	3,200 mg/day
indomethacin (Indocin [®])	25 PO BID-TID	200 mg/day
indomethacin SR (Indocin SR [®])	75 mg PO QD-BID	150 mg/day
ketoprofen (Orudis [®])	50 mg PO QID or 75 mg PO TID	300 mg/day
meloxicam (Mobic [®])	7.5 mg – 15 mg PO QD	15 mg/day
naproxen (Naprosyn [®])	250 – 500 mg PO BID	1,500 mg/day
naproxen sodium (Anaprox [®] , Anaprox DS [®])	275 – 550 mg PO BID	1,650 mg/day
oxaprozin (Daypro [®])	600 – 1,200 mg PO QD	1,800 mg/day
piroxicam (Feldene [®])	10 – 20 mg PO QD	20 mg/day
salsalate (Disalcid [®])	1,500 mg PO BID or 1,000 mg PO TID	3,000 mg/day
sulindac (Clinoril [®])	150 mg – 200 mg PO BID	400 mg/day
tolmetin	400 – 600 mg PO TID	1,800 mg/day
meclofenamate	50 – 100 mg PO Q4-6hr	400 mg/day

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

[†]Off-label indication

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): hypersensitivity to naproxen, esomeprazole magnesium, substituted benzimidazoles, or to any components of the drug product including omeprazole; history of asthma, urticaria, or other allergic-type reactions to aspirin or other NSAIDs; in the setting of coronary artery bypass graft (CABG) surgery; concurrent use of rilpivirine-containing products
- Boxed warning(s): risk of serious cardiovascular and gastrointestinal events
 - NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.
 - NSAIDs, including naproxen, cause an increased risk of serious GI adverse events including bleeding, ulceration, and perforation of the stomach or intestines.
 - Vimovo is contraindicated in the setting of CABG surgery.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Rheumatoid arthritis, osteoarthritis, and	One tablet PO BID of either 375 mg naproxen/20 mg esomeprazole or 500 mg naproxen/20 mg esomeprazole	1,000 mg naproxen/40mg esomeprazole per day

Indication	Dosing Regimen	Maximum Dose
ankylosing spondylitis		
JIA	≥ 50 kg: One tablet PO BID of either 375 mg naproxen/20 mg esomeprazole or 500 mg naproxen/20 mg esomeprazole 38 kg to < 50 kg: 375 mg naproxen/20 mg esomeprazole PO BID	≥ 50 kg: 1,000 mg naproxen/40mg esomeprazole per day 38 kg to < 50 kg: 750 mg naproxen/40 mg esomeprazole per day

VI. Product Availability

Delayed-release tablets (enteric-coated naproxen/immediate-release esomeprazole):
375 mg/20 mg, 500 mg/20 mg

VII. References

1. Vimovo Prescribing Information. Lake Forest, IL: Horizon Pharma USA, Inc.; November 2024. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/VIMOVO/vimovo_fpi_english.pdf. Accessed January 30, 2026.
2. Micromedex® Healthcare Series [Internet Database]. Ann Arbor, Michigan: Merative™. Updated periodically. January 30, 2026.
3. Clinical Pharmacology [database online]. Philadelphia, PA: Elsevier. Updated periodically. Available at: <http://www.clinicalkey.com/pharmacology>. Accessed January 30, 2026.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
2Q 2022 annual review: no significant changes; added risk factors for developing NSAID-induced gastric ulcers to criteria; references reviewed and updated.	01.18.22	05.22
Template changes applied to other diagnoses/indications and continued therapy section.	10.03.22	
2Q 2023 annual review: no significant changes; added quantity limit for adolescents with weight 38 kg to < 50 kg; references reviewed and updated.	01.23.23	05.23
2Q 2024 annual review: for commercial line of business, updated approval duration from length of benefit to “12 months”; request for generic formation added to continued therapy; references reviewed and updated.	01.18.24	05.24
2Q 2025 annual review: clarified generic naproxen-esomeprazole applies to policy; references reviewed and updated.	01.16.25	05.25
Added step therapy bypass for IL HIM per IL HB 5395.	06.27.25	
2Q 2026 annual review: no significant changes; references reviewed and updated. Added ICHRA line of business.	03.30.26	05.26

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.